Cryolife Inc (CRY) reported quarterly earnings results on Monday, Jul-25-2016. The company said it had a profit of $0.13 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.07. Analysts had a consensus of $0.06. The company posted revenue of $47.08 million in the period, compared to analysts expectations of $44.16 million. The company’s revenue was up 32.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.03 EPS.
Many Wall Street Analysts have commented on Cryolife Inc. Lake Street Initiated Cryolife Inc on Jun 15, 2016 to “Buy”, Price Target of the shares are set at $15.Cryolife Inc was Downgraded by Ladenburg Thalmann to ” Neutral” on Apr 28, 2016.
Cryolife Inc opened for trading at $12 and hit $12.2 on the upside on Wednesday, eventually ending the session at $12.13, with a gain of 1.34% or 0.16 points. The heightened volatility saw the trading volume jump to 59,462 shares. Company has a market cap of $396 M.
In a different news, on Jun 3, 2016, Ronald D Mccall (director) sold 10,000 shares at $11.56 per share price. According to the SEC, on May 12, 2016, James Benson (director) sold 5,000 shares at $12.22 per share price. On Apr 19, 2016, C Elkins Ronald (director) sold 1,000 shares at $12.00 per share price, according to the Form-4 filing with the securities and exchange commission.
CryoLife Inc. (CryoLife) is a medical device company. The Company is engaged in medical device manufacturing and distribution and in the processing and distribution of implantable human tissues for cardiac and vascular surgeries. The Company operates in two segments: Medical Devices and Preservation Services. The Medical Devices segment includes external revenues from product sales of BioGlue BioFoam PerClot CardioGenesis cardiac laser therapy HeRO Graft and ProCol. The Preservation Services segment includes external services revenues from the preservation of cardiac and vascular tissues. The Company’s product BioGlue is a polymer consisting of bovine blood protein and an agent for cross-linking proteins which was developed for use in cardiac vascular pulmonary and surgical applications. The Company developed BioFoam to seal organs such as the liver and for use in cardiovascular surgeries and provide hemostasis in penetrating wounds and trauma.